Novo Nordisk CEO encouraged by Saxenda's role in obesity business growth

The growth of Novo Nordisk's obesity business cannot all be ascribed to the new weight loss drug Wegovy, says Novo Nordisk CEO Lars Fruergaard Jørgensen. Its predecessor, Saxenda, is also doing well, reports the CEO.

Photo: Stine Bidstrup/ERH

Although Novo Nordisk still doesn't want to report the individual sales figures for its two obesity treatments – Saxenda and its heir, Wegovy – the positive progress in the business area is there for anyone to see in Wednesday's quarterly report.

In the first nine months of the year, Novo Nordisk total sales for the weight loss treatments amounted to DKK 5.9bn (USD 919m), beating full-year sales figures from the business of DKK 5.6bn (USD 872.2m) from 2020. That figure consisted only of Saxenda sales, as Wegovy was only introduced to the US market in June of this year – which is also its only market so far. 

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs